Local therapy of primary disease and survival in non-small cell lung cancer metastatic to brain and other single organ sites

Abstract

19020 Background: Standard therapy for non-small cell lung cancer (NSCLC) brain metastases is radiotherapy and/or surgical resection for all visible lesions. This practice has been able to palliate brain metastasis-related symptoms and to improve survival. Similarly, we hypothesize that local therapy for other sites of disease, particularly the primary tumor and locoregional lymph node metastases, may further improve survival. Methods: Patients with NSCLC metastatic to one organ site were identified in the M.D. Anderson Cancer Center Tumor Registry, Thoracic Radiation Oncology, and Neurosurgery databases, and survival was compared for patients who received definitive local therapy of primary disease - chest radiotherapy >/= 45 Gy (ChRT) or thoracic resection (TS) of their primary tumor and locoregional lymph nodes - versus those who did not. Results: 120 patients had brain as a solitary organ site of metastasis, and 115 (96%) received brain metastasis treatment with surgical resection, stereotactic radios...